We’re excited to share that Juan Mantelle, COO of ProSolus, Inc., is featured in the 2016 PharmaVOICE 100 issue, in the Commanders & Chiefs section. Congratulations Juan! The PharmaVoice 100 is a list of inspirational leaders, representing a wide range of industry sectors and functional areas, who are having an extraordinary and positive impact on…Details
Acquisition adds cutting-edge expertise in transdermal drug development and manufacturing SAN ANTONIO, TX — Effective May 29, 2015, Mission Pharmacal Company (“Mission”) has acquired the assets of ProSolus Pharmaceuticals LP headquartered in Miami, Fla. Mission’s wholly-owned subsidiary, ProSolus Inc., offers unrivaled expertise in the development and manufacturing of sophisticated and convenient transdermal (through the skin) drug…Details
ProSolus, Inc. is proud to announce the upcoming launch of LidoFlex, developed in conjunction with Mission Pharmacal and Richmar. LidoFlex has a 4% Lidocaine concentration, which is the highest concentration available without a prescription.
ProSolus is proud to announce that we have won the Life Sciences Award, sponsored by FPL. Learn more about ProSolus Pharmaceuticals, and our plans for growth in the South Florida area.
Beacon Counsel Key Ceremony
ProSolus Pharmaceuticals is among more than 30 companies honored during the Beacon Counsel 2011 Key Ceremony and Holiday Reception.